‘Viral Immunotherapy Meets AI Technology’
STRASBOURG, France–(BUSINESS WIRE)–#Transgene–Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that its Executive Vice President and Chief Scientific Officer, Eric Quéméneur, Pharm.D., PhD, will present today at the virtual 5th Annual Neoantigen Based Therapies Summit.
Presentation
- Title: Viral Immunotherapy Meets AI Technology
- Session: Clinical Translation – Utilizing Different Delivery Platforms to Enhance Clinical
- Timing: November 5th at 11.45 am ET / 5.45 pm CET
Éric Quéméneur, Pharm.D., Ph.D., Executive VP and Chief Scientific Officer of Transgene, said: “Viral immunotherapy constitutes a very promising modality based on harnessing the natural capabilities of the immune system to target cancer cells. TG4050 is an individualized cancer vaccine based on our myvac® technology that has the ability to elicit an immune response against up to 30 patient-specific tumor neoantigens. Our partnership with NEC enables us to benefit from its cutting-edge AI capabilities that allows us to select the best combination of neoantigens to include in TG4050 to induce a strong anti-tumor immune response. We are convinced that the success of TG4050, which is at the crossroad of immunotherapy and big data sciences, will herald the start of a new era in the fight against cancer. (Read more…)”
The Neoantigen Based Therapies Summit is the leading end-to-end meeting dedicated to delivering the promise of accurate identification, prediction, and validation of neoantigens to develop highly efficacious vaccines and cell therapies.
***
About TG4050
TG4050 is an individualized cancer vaccine based on the myvac® platform; it is based on an optimized viral platform for cancer vaccination and integrates NEC’s artificial intelligence capabilities. This therapeutic vaccine aims at stimulating the immune system of patients to induce a T-cell response against tumor-specific antigenic alterations, called neoantigens. These neoantigens are derived from genomic mutations and selected using NEC’s Neoantigen Prediction System, an advanced AI technology that has already been applied in the field of oncology. TG4050 has been designed to target up to 30 patient-specific neoantigens. Transgene is sponsoring two Phase 1 trials that are expected to deliver a first proof of concept of this virus-based individualized approach.
About Transgene
Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at: www.transgene.fr.
Follow us on Twitter: @TransgeneSA
Disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Contacts
Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media:
Citigate Dewe Rogerson
David Dible/Sylvie Berrebi
+ 44 (0)20 7638 9571
transgene@citigatedewerogerson.com